Resonance Health specializes in the development and delivery of non-invasive medical imaging software and services, primarily focusing on liver iron and fat quantification. The company's flagship product, FerriScan, is globally recognized as the gold standard for the quantitative measurement of liver iron concentration, aiding in the management of conditions such as thalassaemia, sickle cell disease, haemochromatosis, and myelodysplastic syndrome. Resonance Health serves a diverse clientele, including clinicians, patients, pharmaceutical companies, and clinical trial organizations. Operating in the healthcare and medical imaging market, the company generates revenue through the provision of imaging services, clinical trial support, and software licensing. Resonance Health's business model is centered on providing high-quality, regulatory-cleared imaging solutions that enhance patient care and support clinical research. The company is committed to innovation, as evidenced by its recent regulatory clearances and provisional patents.

Keywords: liver iron quantification, FerriScan, non-invasive imaging, thalassaemia, sickle cell disease, haemochromatosis, myelodysplastic syndrome, clinical trials, MRI analysis, regulatory clearance.